


The background features a light gray gradient with several overlapping geometric shapes. A large, light gray diamond is centered, with a smaller, darker gray diamond to its left. In the top right and bottom left corners, there are faint, semi-transparent white circles.

Lymphoma

《 Diagnosis and treatment of lymphoma consensus 》 – (Hodgkin' s lymphoma)



1. B symptoms : fever, night sweating, body weight loss.

2. Poor prognostic factors: ESR>50, B symptoms, Nodal sites >3, bulky tumor(>10) or large mediastinum lesion(MMR>0.33).


3. Clinical trial is always an option of treatment.

《Diagnosis and treatment of lymphoma consensus》 – CLASSICAL HODGKIN LYMPHOMA(CHL)

Clinical Stage	Bulky Mediastinal Disease or >10 cm Adenopathy	ESR>50 or #Sites>3	Guidelines Page
I / IIA	No	NO	Favorable Disease
	No	Yes	Favorable /Unfavorable Disease
	Yes	Yes/NO	Unfavorable Disease
IB / IIB	Yes / No	Yes/NO	Unfavorable Disease
III - IV	Yes / No	N/A	Advanced Disease

《 Diagnosis and treatment of lymphoma consensus 》 – (Hodgkin's lymphoma)

Organizational pattern : Classic Hodgkin's Lymphoma




1.Clinical trial is always an option of treatment.

2.Rituximab may be added electively (self-paid) if CD 20 is positive in IHC stain.

3. A good definition of early prognosis: 1.Age< 50 y/o 2.ESR normal 3.Stage I~II 4.No B symptoms 5.No bulky disease


《 Diagnosis and treatment of lymphoma consensus 》 — (Hodgkin's lymphoma)

Organizational pattern : Classic Hodgkin's



《 Diagnosis and treatment of lymphoma consensus 》 — (Hodgkin's lymphoma)


Organizational pattern : Classic Hodgkin's Lymphoma



-
1. Clinical trial is always an option of treatment.
 2. It means a huge tumor bulky mediastinal disease or ≥ 10 cm.
- * Reevaluation(PET-CT) after chemotherapy at least 2-4 cycles
- ** Total 6 cycles


《 Diagnosis and treatment of lymphoma consensus 》 —(Hodgkin' s lymphoma)

Organizational pattern : Classic Hodgkin's Lymphoma



《 Diagnosis and treatment of lymphoma consensus 》 — (Hodgkin's lymphoma)


Organizational pattern : Nodular lymphocyte–predominant Hodgkin's Lymphoma



* Reevaluation(PET-CT) after chemotherapy at least 2-4 cycles

· Clinical trial is always an option of treatment.

《 Diagnosis and treatment of lymphoma consensus 》 — Chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL)




《 Diagnosis and treatment of lymphoma consensus 》 — (Follicular Lymphoma) Grade1-2

Clinical examination

Clinical stage


The main treatment




* Rituximab Persistent treatment is administered every 3 months for 2 years, only for follicular lymphoma (Gr. I-III)

• Clinical trial is always an option of treatment.


《Diagnosis and treatment of lymphoma consensus》 — Diffuse large B-cell lymphoma / follicular lymphoma Gr.III(DLBCL/FL Gr.III)



《Diagnosis and treatment of lymphoma consensus》— Follicular lymphoma transformed into diffuse large B-cell lymphoma (FL → DLBCL)




《 Diagnosis and treatment of lymphoma consensus 》 — (Gastric MALT lymphoma) 》



• Clinical trial is always an option of treatment.

《Diagnosis and treatment of lymphoma consensus》— T-cell lymphoma (Cutaneous T-cell lymphoma and T-immunoblastic lymphoma are not included)



-
1. Clinical trial is always an option of treatment.
 2. Treatment with diffuse large B cell lymphoma without rituximab.
 3. aalPI: Age - adjusted International Prognostic Index

《 Reference 》

1. NCCN clinical practice guidelines in oncology-Hodgkin Lymphoma. version 4.2021.
2. NCCN clinical practice guidelines in oncology-B-cell Lymphoma. Version 5.2021.
3. NCCN clinical practice guidelines in oncology-T-cell Lymphoma. Version 1.2021.
4. NCCN clinical practice guidelines in oncology-Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 1.2022
5. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *J Clin Oncol* 2014;32:3059-3068.
6. Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. *Lancet* 2013;381:1817-1826.
7. Eichhorst B, Fink AM, Busch R, et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): Final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study)[abstract]. *Blood* 2014;124:Abstract 19.
8. Flinn IW, van der Jagt R, Kahl BS, et al. Open-label, randomized, noninferiority study of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of advanced indolent NHL or MCL: the BRIGHT study. *Blood* 2014;123:2944-2952.
9. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. *Lancet* 2013;381:1203-1210. Flinn IW, van der Jagt R, Kahl BS, et al. Open-label, randomized, noninferiority study of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of advanced indolent NHL or MCL: the BRIGHT study. *Blood* 2014;123:2944-2952.
10. Salles, G, Seymour JF, Feugier P, et al. Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab

- maintenance in follicular lymphoma patients responding to frontline immunochemotherapy [abstract]. *Blood* 2013;122:Abstract 509.
11. Radford J, et al. Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin Lymphoma and a negative PET scan after 3 cycles of ABVD. results of the UK NCRI RAPID Trial [abstract]. *Blood* 2012; 120:Abstract 547.
 12. Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. *J Clin Oncol* 2012;30:3209-3216. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine
 13. Meyer R, Gospodarowicz M, Connors J, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. *N Engl J Med* 2012;366:399-408.
 14. Salles GA, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. *The Lancet* 2011;377:42-51.
 15. Salles GA, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. *The Lancet* 2011;377:42-51.
 16. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. *Blood* 2010;116:2040-2045.
 17. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. *J Clin Oncol* 2010;28:4184-4190.

18. WHO classification of tumours of haematopoietic and lymphoid tissues. In: Swerdlow SH, Campo E, Harris NL, et al., eds (ed 4). Lyon, France: IARC; 2008
19. Fernández de Larrea C, Martínez C, et al. Salvage chemotherapy with alternating MINE- ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem cell transplantation. *Ann Oncol* 2010;21(6):1211-1216.
20. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. *J Clin Oncol* 2005;23:4117-4126.
21. NCCN clinical practice guidelines in oncology- Hodgkin Lymphoma. Version 1.2023—September 16, 2022

